Myocardial stiffness plays an important role in cardiac function. Increased stiffness in the myocardium can cause poor function and restrictive diastolic filling, which can lead to heart failure symptoms, even with a normal left ventricular (LV) ejection fraction.[1](#jmri25678-bib-0001){ref-type="ref"} Myocardial infarcts can cause abnormal tissue stiffness that can affect LV wall stress and the pattern of LV remodeling.[2](#jmri25678-bib-0002){ref-type="ref"} However, there is currently no conventional imaging technique for directly measuring myocardial stiffness *in vivo*. *In vivo* myocardial stiffness may be inferred from pressure--volume relationships, which are invasive and rarely performed in clinical practice.[3](#jmri25678-bib-0003){ref-type="ref"} Noninvasive strain imaging, performed with either ultrasound[4](#jmri25678-bib-0004){ref-type="ref"} or magnetic resonance imaging (MRI),[5](#jmri25678-bib-0005){ref-type="ref"} measures tissue displacements throughout the cardiac cycle, which in actively contracting myocardium is a measure of tissue contraction, and not stiffness.[6](#jmri25678-bib-0006){ref-type="ref"}, [7](#jmri25678-bib-0007){ref-type="ref"}

Shear wave elastography is an emerging imaging approach for measuring myocardial stiffness *in vivo*.[8](#jmri25678-bib-0008){ref-type="ref"}, [9](#jmri25678-bib-0009){ref-type="ref"}, [10](#jmri25678-bib-0010){ref-type="ref"}, [11](#jmri25678-bib-0011){ref-type="ref"}, [12](#jmri25678-bib-0012){ref-type="ref"}, [13](#jmri25678-bib-0013){ref-type="ref"}, [14](#jmri25678-bib-0014){ref-type="ref"}, [15](#jmri25678-bib-0015){ref-type="ref"} Shear wave elastography approaches rely on an external vibrating source to generate shear waves inside a tissue of interest. An imaging technique (either MRI or ultrasound) then measures the vibrational displacements in the tissue.[8](#jmri25678-bib-0008){ref-type="ref"}, [9](#jmri25678-bib-0009){ref-type="ref"}, [10](#jmri25678-bib-0010){ref-type="ref"}, [11](#jmri25678-bib-0011){ref-type="ref"}, [12](#jmri25678-bib-0012){ref-type="ref"}, [13](#jmri25678-bib-0013){ref-type="ref"}, [14](#jmri25678-bib-0014){ref-type="ref"}, [15](#jmri25678-bib-0015){ref-type="ref"} The displacement field is used to calculate a stiffness map through one of several mathematical techniques collectively referred to as inversion algorithms.[16](#jmri25678-bib-0016){ref-type="ref"}

Currently, a 3D high‐frequency cardiac MR elastography (MRE) technique is being developed, which has shown a high level of concordance with dynamic material testing[17](#jmri25678-bib-0017){ref-type="ref"} and has been shown to be feasible in normal volunteers.[18](#jmri25678-bib-0018){ref-type="ref"}

Cardiac amyloidosis leads to myocardial stiffness, where stiffness is inferred from existing *ex vivo* and *in vivo* techniques,[19](#jmri25678-bib-0019){ref-type="ref"}, [20](#jmri25678-bib-0020){ref-type="ref"}, [21](#jmri25678-bib-0021){ref-type="ref"}, [22](#jmri25678-bib-0022){ref-type="ref"}, [23](#jmri25678-bib-0023){ref-type="ref"} and therefore this patient group is an excellent cohort to validate whether or not 3D cardiac MRE can detect changes in stiffness in a patient population. Amyloid fibrils have been shown to have increased stiffness when using dynamic testing with 4D electron microscopy.[19](#jmri25678-bib-0019){ref-type="ref"} Amyloid infiltrated explanted human myocardial trabecula have increased stiffness by length--tension relationships.[24](#jmri25678-bib-0024){ref-type="ref"} Patients with cardiac amyloid have increased LV diastolic pressures with decreased LV volumes, indicating increased global myocardial stiffness.[20](#jmri25678-bib-0020){ref-type="ref"}, [21](#jmri25678-bib-0021){ref-type="ref"} At autopsy, amyloid infiltrative hearts are described as firm, waxy, and rubbery.[25](#jmri25678-bib-0025){ref-type="ref"} For these reasons, cardiac amyloidosis has been referred to as the "stiff heart syndrome."[22](#jmri25678-bib-0022){ref-type="ref"}, [23](#jmri25678-bib-0023){ref-type="ref"} This patient population is ideal for accessing and validating *in vivo* cardiac MRE stiffness measurements.

Therefore, the objective of this study was to evaluate if 3D high‐frequency cardiac MRE can measure increased stiffness in patients with cardiac amyloidosis as compared with healthy volunteers.

Materials and Methods {#jmri25678-sec-0007}
=====================

Study Population {#jmri25678-sec-0008}
----------------

Twenty‐two patients with cardiac amyloidosis and 16 healthy volunteers were enrolled in this study after approval by our Institutional Review Board and written informed consent was received from each subject. All subjects underwent cardiac MRI/MRE and echocardiography with speckle tracking strain imaging Doppler evaluation of diastolic function.

Patients with tissue diagnosis of amyloidosis and LV maximal wall thickness of greater than 12 mm by echocardiography were classified as having cardiac amyloidosis.[26](#jmri25678-bib-0026){ref-type="ref"} Thirteen of the 22 patients had right ventricular (RV) biopsy confirmed cardiac amyloidosis. In the remaining nine patients, tissue was obtained from fat aspirate, muscle, kidney, and/or bone marrow.

Healthy volunteers had no history of coronary artery disease, heart failure, hypertension, hypertensive medication, valvular heart disease, congenital heart disease, or diabetes. The healthy volunteers had no symptoms of chest pain or shortness of breath, and exhibited normal heart sounds, normal breath sounds, had a systolic blood pressure of less than 140 mmHg, and a diastolic blood pressure of less than 90 mmHg. Healthy volunteers were selected to fall within the same age range (50--85 years old) and have a similar male‐to‐female ratio as the amyloidosis patients.

All subjects were excluded if they had any contraindications or relative contraindications to MRI scanning.

MRE {#jmri25678-sec-0009}
---

### MRI/MRE: Acquisition {#jmri25678-sec-0010}

Cardiac MRE was used to quantitatively measure myocardial stiffness across the LV of each subject. The experimental setup is shown in Fig. [1](#jmri25678-fig-0001){ref-type="fig"}. An active driver, outside of the scan room, generated acoustic vibrations that were transmitted through acoustic tubing to a passive driver in contact with the subject. The passive driver surface was coated with acoustic gel and placed in direct contact with the subject\'s skin, just to the left of the sternum and superior to the xiphoid process. An elastic tension strap was used to keep the passive driver in place and to help improve coupling between the passive driver diaphragm and the volunteer\'s skin surface. To help avoid signal interference from shear wave vibrations, cardiac gating was performed by placing electrocardiography leads on the back of the left shoulder of each subject instead of on the chest.

![Cardiac MRE experimental setup. An active driver delivers 140 Hz vibrations through acoustic tubing to a passive cardiac driver that is strapped to the subject\'s chest. Shear waves are transmitted into the myocardium and the wave displacement field is imaged with the MRI.](JMRI-46-1361-g001){#jmri25678-fig-0001}

Imaging was performed with a 1.5T closed‐bore MR imager (Optima MR450W; GE Healthcare, Milwaukee, WI) in an oblique orientation to obtain short‐axis MRE images of the heart using the built‐in, receive‐only, integrated whole‐body phased array system (GEM anterior--posterior array, GE Healthcare). Imaging was conducted using the same procedure as previously described.[18](#jmri25678-bib-0018){ref-type="ref"} Only a vibration frequency of 140 Hz was used; however, the previous study demonstrated that it gave the highest median octahedral shear strain signal‐to‐noise ratio (OSS‐SNR) across the LV volume in healthy volunteers when compared with frequencies of 80 Hz, 100 Hz, 180 Hz, and 220 Hz. Briefly, a flow‐compensated, cardiac‐gated, spin‐echo, single‐shot echo planar imaging MRE sequence was used with TR matched to each volunteer\'s heart rate with electrocardiogram‐gating, TE = 69 msec; field of view (FOV) = 32 cm; 64 × 64 image matrix; parallel imaging acceleration factor = 2; 5 contiguous 5‐mm‐thick axial slices; two motion‐encoding gradient pairs on each side of the refocusing pulse matched to the vibration frequency; alternating x, y, z, and 0 motion‐encoding gradient directions; and four phase offsets spaced evenly over one vibration period. For image processing purposes the image matrix was reformatted to 256 × 256 × 20 to give an isotropic voxel size of 1.25 mm. Images were acquired at the minimum delay possible in the cardiac cycle (∼100 msec) after the R‐wave ECG trigger, which is believed to be the most reproducible phase in the cardiac cycle.

For measurement of myocardial mass and volumes, cardiac MRI balanced steady‐state free precession (bSSFP) images were obtained in the short axis. The following imaging parameters were used to acquire 15 slices with the bSSFP acquisition; FOV 38 cm, imaging matrix 224 × 224, TR/TE = 3.3/1.1, slice thickness 8 mm, flip angle 60°, and a total scan time of ∼2 minutes with 15 breath‐holds of ∼17 seconds (depending on the heart rate).

### MRE: Postprocessing/Inversion {#jmri25678-sec-0011}

MRE inversion was implemented by taking the curl of the 3D displacement field and performing a 3D local frequency estimation algorithm (LFE)[16](#jmri25678-bib-0016){ref-type="ref"}, [27](#jmri25678-bib-0027){ref-type="ref"} to invert the wave‐field and generate stiffness maps. The LFE algorithm was chosen because it is very robust in the presence of noise and is not affected by wave reflections. The LV of the heart was semiautomatically segmented using a random walker segmentation algorithm[28](#jmri25678-bib-0028){ref-type="ref"} and a previously described quantitative quality factor referred to as the OSS‐SNR was calculated on the curl wave fields. The LV mask was eroded by two pixels in all directions to reduce edge effects. The median stiffness and mean (OSS‐SNR) over the remaining volume were measured.

To establish a baseline of noise, the MRE exam was repeated with the vibrational motion turned off ("no motion" scan) and OSS‐SNR[29](#jmri25678-bib-0029){ref-type="ref"} was calculated. An MRE exam was considered successful only if the mean OSS‐SNR in the myocardium was at least two standard deviations above the mean OSS‐SNR of all "no‐motion" scans (ie, noise) across all subjects.

### Cardiac MRI Processing {#jmri25678-sec-0012}

The short axis bSSFP images were used to calculate LV mass and volumes using commercially available software (cvi42, Circle Cardiovascular Imaging, Calgary, Alberta, Canada) by manually tracing the LV endocardial and epicardial contours.

Echocardiography {#jmri25678-sec-0013}
----------------

Echocardiography was performed on all subjects. Diastology data (early filling velocity \[E velocity\], late filling velocity \[A velocity\], the E/A ratio, the diastolic peak velocities of the medial mitral annulus \[e\' medial\], and the E/e\' ratio) were obtained at the apical 4‐chamber acoustic window using 2D and Doppler color flow techniques. Left atrial maximal volume was calculated with the method of discs from the 2‐chamber and 4‐chamber views. Global, average, peak systolic longitudinal strain, and basal, average, peak, and systolic strain were obtained using speckle tracking techniques.

Statistical Analysis {#jmri25678-sec-0014}
--------------------

The cardiac amyloidosis patients were compared to healthy volunteers with respect to MRE stiffness, cardiac MRI mass and volumes, and echocardiography diastolic and strain parameters using a commercial software package (OriginPro 2015, OriginLab, Northampton, MA) that implemented a Mann--Whitney *U*‐test of significance.[30](#jmri25678-bib-0030){ref-type="ref"} For the MRE stiffness measurements a one‐sided Mann--Whitney *U*‐test was used to see if there was an elevated stiffness in the cardiac amyloidosis patient group. All other metrics were tested for difference using a two‐sided test. *P* \< 0.05 was considered statistically significant.

Results {#jmri25678-sec-0015}
=======

Study Population {#jmri25678-sec-0016}
----------------

Eleven healthy volunteers and 16 patients with cardiac amyloidosis had sufficient image quality to be included in the MRE analysis. The population demographics of all subjects included in the study are summarized in Table [1](#jmri25678-tbl-0001){ref-type="table-wrap"}.

###### 

Study Population Demographics

                                    Normal                        Amyloid                       *P* value
  --------------------------------- ----------------------------- ----------------------------- -----------
  Median age (years)                57 (min: 52, max: 84)         66.5 (min: 50, max 85)        0.27
  Sex (m/f)                         (10/1)                        (13/3)                        0.52
  Amyloid subtype                   Na                            AL (10), TTR (6)              Na
  NYHA class (0‐IV)                 0                             1 (4), 2 (6), 3(6)            Na
  Median body surface area (m^2^)   2.00 (min: 1.61, max: 2.29)   2.01 (min: 1.64, max: 2.23)   0.79
  Systolic BP (mmHg)                118 (min: 104, max: 142)      118.7 (min: 82, max: 148)     1
  Diastolic BP (mmHg)               66 (min: 60, max: 73)         66 (min: 54, max: 98)         0.60

m/f: male/female; NYHA: New York Heart Association; BP: blood pressure.

MRE Exam Quality Factor {#jmri25678-sec-0017}
-----------------------

The group‐wise median OSS‐SNR for the "no motion" scans was 0.96 and an OSS‐SNR value of 1.17 (2 SD above the median) was used as a quantitative quality factor threshold to exclude MRE exams with poor image quality (Fig. [2](#jmri25678-fig-0002){ref-type="fig"}). The mean OSS‐SNR of five volunteers and six patients fell below this threshold and thus these exams were excluded from the study.

![Wave quality factor metric. An example of a wave image from the same subject **(A)** with vibrational motion on ("Motion"), and **(B)** with vibrational motion turned off ("No‐Motion"). The mean OSS‐SNR over the entire myocardial volume for each scan is reported at the bottom of each wave image. **(C)** Mean OSS‐SNR across the myocardium for "Motion" and "No‐Motion" scans across all subjects. The dotted line is two standard deviations above the mean OSS‐SNR from "No‐Motion" scans, and only scans with values above this threshold were included in the study.](JMRI-46-1361-g002){#jmri25678-fig-0002}

Cardiac MRE Stiffness Measurements {#jmri25678-sec-0018}
----------------------------------

The LV myocardial stiffness of the 16 cardiac amyloid patients (median: 11.4 kPa, min: 9.2, max: 15.7) measured with cardiac MRE was significantly higher (*P* \< 0.01) than the LV myocardium of 11 normal healthy volunteers (median: 8.2 kPa, min: 7.2, max: 11.8) (Fig. [3](#jmri25678-fig-0003){ref-type="fig"}). Typical short‐axis bSSFP images and elastograms from the mid‐section of the left ventricle in a healthy volunteer and an age‐ and sex‐matched amyloidosis patient are shown in Fig. [4](#jmri25678-fig-0004){ref-type="fig"}. The MRE stiffness values for each group are listed at the top of Table [2](#jmri25678-tbl-0002){ref-type="table-wrap"}.

![Box‐and‐whisker plot of median myocardial stiffness (kPa) in patients diagnosed with amyloidosis and normal healthy controls. The bottom and top of the box represent the 1^st^ and 3^rd^ quartiles, the line within the box represents the median value, the square in the box represents the mean, and the whiskers represent 1.5 SD from the mean. Patients in the amyloidosis group had significantly stiffer myocardial tissue (*P* \< 0.01) than age‐ and sex‐matched controls.](JMRI-46-1361-g003){#jmri25678-fig-0003}

![bSSFP Images and MRE elastograms. **(A,B)** Central slice short‐axis early systole bSSFP images of the heart in a healthy volunteer (mean stiffness = 7.2 kPa) and an age‐ and sex‐matched patient with amyloidosis (mean stiffness = 15.7 kPa), respectively. **(C,D)** The respective stiffness maps (elastograms).](JMRI-46-1361-g004){#jmri25678-fig-0004}

###### 

Diagnostic Parameters

                                       Normal                         Amyloid                         *P* value
  ------------------------------------ ------------------------------ ------------------------------- --------------
  MRE stiffness                                                                                       
  Median myocardial stiffness (kPa)    8.29 (min: 7.21, max: 11.83)   11.36 (min: 9.15, max: 15.68)   *P \< * 0.01
  Echocardiography                                                                                    
  Longitudinal strain (%)              −21 (min: ‐24, max: ‐20)       −9 (min: ‐17, max: ‐4)          *P \< * 0.01
  Basal average strain (%)             −20 (min: ‐21, max: ‐17)       −5 (min: ‐17, max: ‐2)          *P \< * 0.01
  Left atrial volume index (mL/m^2^)   29.5 (min: 20, max: 40)        43 (min: 30, max: 73)           *P \< * 0.01
  E velocity                           0.75 (min: 0.6, max: 0.9)      0.8 (min: 0.6, max: 1.1)        *P = * 0.42
  A velocity                           0.65 (min: 0.4, max: 1)        0.5 (min: 0.2, max: 1.1)        *P = * 0.20
  E/A                                  1.07 (min: 0.875, max: 2)      2 (min: 0.6, max: 3.67)         *P = * 0.10
  e\' medial                           0.085 (min:0.06, max: 0.12)    0.04 (min:0.02, max: 0.06)      *P \< * 0.01
  E/e\'                                8.4 (min: 5.8, max: 15)        20 (min: 12, max: 45)           *P \< * 0.01
  MRI volumes/mass                                                                                    
  Diastolic wall thickness (mm)        9 (min: 8, max: 14)            18.5 (min: 14, max: 33)         *P \< * 0.01
  Systolic wall thickness (mm)         16 (min: 13, max: 19)          23 (min: 19, max: 32)           *P \< * 0.01
  LVEDVi (mL/ m^2^)                    66 (min: 39, max: 83)          65.5 (min: 46, max: 104)        *P = * 0.60
  LVESVi (mL/ m^2^)                    21 (min: 13, max: 28)          32 (min: 18, max: 62)           *P \< * 0.01
  LVSVi (mL/ m^2^)                     42 (min: 25, max: 62)          31 (min: 17, max: 69)           *P = * 0.13
  LVEF (%)                             65 (min: 59, max: 75)          46 (min: 32, max: 74)           *P \< * 0.01
  LV mass (g)                          70 (min: 38, max: 86)          121 (min: 73, max: 190)         *P \< * 0.01

A‐velocity: late filling velocity; E‐velocity: early filling velocity; e\' medial: the diastolic peak velocities of the medial mitral annulus; kPa: kilopascal; LV: left ventricle; MRE: magnetic resonance elastography; RV: right ventricle; NYHA: New York Heart Association; LVEDVi: left ventricle end‐diastolic volume index; LVESVi: left ventricle end‐systolic volume index; LVSVi: left ventricle systolic volume index; LVEF: left ventricle ejection fraction.

Cardiac MRI and Echocardiography {#jmri25678-sec-0019}
--------------------------------

The bSSFP imaging demonstrated that patients with amyloidosis had significantly thicker diastolic and systolic LV wall thickness, a greater LVEDVi and LV mass, and lower LVEF than normal healthy volunteers. Echocardiography showed that the amyloidosis group had significantly lower e\', increased E/e\' ratio, lower longitudinal and basal strain, and greater left atrial volume index than the healthy volunteer group. All bSSFP and echocardiography parameters are listed in Table [2](#jmri25678-tbl-0002){ref-type="table-wrap"}.

Discussion {#jmri25678-sec-0020}
==========

This study demonstrates the feasibility of 3D high‐frequency cardiac MRE as a contrast‐agent‐free diagnostic imaging technique for quantitatively measuring myocardial stiffness *in vivo*. Elgeti et al. used a shear wave amplitude measurement MRE technique[31](#jmri25678-bib-0031){ref-type="ref"} to distinguish patients with diastolic abnormalities at echocardiography from normal subjects.[10](#jmri25678-bib-0010){ref-type="ref"}, [11](#jmri25678-bib-0011){ref-type="ref"}, [32](#jmri25678-bib-0032){ref-type="ref"} However, their technique did not acquire 3D displacement fields and there was no attempt to quantitate myocardial stiffness. Instead, they reported the mean amplitudes of the shear wave displacement as a surrogate for myocardial stiffness.[11](#jmri25678-bib-0011){ref-type="ref"}, [32](#jmri25678-bib-0032){ref-type="ref"}, [33](#jmri25678-bib-0033){ref-type="ref"} Wassenaar et al.[34](#jmri25678-bib-0034){ref-type="ref"} described a quantitative cardiac MRE technique, using 80 Hz vibration frequency and a 2D MRE approach, but to date they have only reported results on normal volunteers and have not demonstrated the ability to distinguish normal subjects from patient populations. Likewise, the cardiac ultrasound elastography literature has primarily focused on demonstrating feasibility in healthy adult and pediatric volunteers and has not been tested in patient populations.[35](#jmri25678-bib-0035){ref-type="ref"}, [36](#jmri25678-bib-0036){ref-type="ref"}

The cardiac amyloid patients in this study had numerous findings traditionally associated with increased myocardial stiffness and served as an excellent group for preliminary validation for cardiac MRE. The cardiac amyloid patients had increased E/e\' ratio and left atrial volume index, which are associated with increased LV filling pressures.[37](#jmri25678-bib-0037){ref-type="ref"}, [38](#jmri25678-bib-0038){ref-type="ref"} E/A was not different between cardiac amyloid patients and normal subjects; however, E/A may be lowered in older normal subjects and is considered to be a less reliable indicator of LV stiffness than other diastolic parameters.[38](#jmri25678-bib-0038){ref-type="ref"} Echocardiographic systolic strain is a measure of myocardial contraction[39](#jmri25678-bib-0039){ref-type="ref"} and is not usually considered a marker of myocardial stiffness unless measured during passive deformation, as in infarcted myocardium.[40](#jmri25678-bib-0040){ref-type="ref"} However, abnormal systolic strain is prognostic in cardiac amyloidosis and considered to be a marker of myocardial infiltration.[7](#jmri25678-bib-0007){ref-type="ref"} Thus, abnormal strain in this study confirms the presence of cardiac amyloidosis and indirectly supports the presence of abnormal stiffness in our patient population.

This study also demonstrated a quantitative threshold that can be used to detect unsuccessful MRE exams in a patient population. In cardiac MRE, the generated stiffness maps can be biased by respiratory motion, poor cardiac gating, inadequate wave penetration, and poor SNR. Prior cardiac MRE studies have used visual inspection to identify low‐quality examinations,[34](#jmri25678-bib-0034){ref-type="ref"} which is not reliable given that the wave fields are complex, or alternatively, included all studies without any quality measures.[11](#jmri25678-bib-0011){ref-type="ref"} To help overcome these challenges we implemented an OSS‐SNR metric to systematically eliminate poorly acquired datasets from our analysis. McGarry et al.[29](#jmri25678-bib-0029){ref-type="ref"} validated OSS‐SNR for accurate inversions for a finite element based algorithm; however, an appropriate OSS‐SNR threshold has not been established for a 3D local frequency estimation algorithm and the imaging parameters used in this study. Both factors play an important role in establishing a threshold of the OSS‐SNR. As a result, "no‐motion" data needed to be acquired in order to establish an OSS‐SNR threshold of 1.17 for the specific cardiac MRE acquisition and postprocessing technique described in this article. With this threshold in place, successful MRE exams could be identified without any need for an MRE expertise to visually inspect exams. This is imperative for the adoption of cardiac MRE in future clinical investigations.

This study had limitations, as it was an early attempt at performing 3D high‐frequency cardiac MRE in a patient population. First, the wave inversion used to generate stiffness maps in this study assumed tissue isotropy and local homogeneity, which are not true in the heart and may introduce errors in the stiffness accuracy. In future studies it may be beneficial to account for anisotropy[13](#jmri25678-bib-0013){ref-type="ref"} in order to improve both inversion algorithms and curl operators for stiffness calculation.[41](#jmri25678-bib-0041){ref-type="ref"}, [42](#jmri25678-bib-0042){ref-type="ref"} Second, in this study we relied on 25‐second breath‐holds (for a heartrate of 60 bpm), which was challenging for some patients. Third, a 5‐mm isotropic acquisition resolution was used, which provided suboptimal spatial resolution and limited interrogation of tissue waves across the myocardium, but was necessary to ensure high SNR and good shear wave detectability. Fourth, only an early systolic phase was investigated with MRE in this study, as this was the most reproducible phase. Measuring multiple phases in the cardiac cycle, particularly end‐diastole, will be desirable in the future for evaluation of restrictive myocardial diseases, which are thought to predominantly affect diastole. Finally, as this was a preliminary study, it had a small population sample. However, the outcomes of this study motivate the investigation of cardiac MRE in larger sample sizes and in different disease populations. Further technological advances such as the implementation of cine EPI MRE imaging, simultaneous multislice imaging,[43](#jmri25678-bib-0043){ref-type="ref"} and more advanced under‐sampling techniques[44](#jmri25678-bib-0044){ref-type="ref"}, [45](#jmri25678-bib-0045){ref-type="ref"} would help increase the number of cardiac phases being measured with MRE and would significantly reduce breath‐hold times and reduce any off‐resonance effects by shortening readout train lengths.

This study demonstrates the feasibility of 3D high‐frequency cardiac MRE as a contrast‐agent‐free diagnostic imaging technique for quantitatively measuring myocardial stiffness, validated in a cardiac amyloidosis patient cohort. The myocardial stiffness of cardiac amyloid patients was found to be significantly stiffer than healthy controls. Furthermore, an OSS‐SNR metric to systematically and objectively exclude unsuccessful MRE exams was successfully implemented in this study. Studies are currently underway to evaluate 3D high‐frequency cardiac MRE in the assessment of myocardial infarcts,[46](#jmri25678-bib-0046){ref-type="ref"} hypertrophic cardiomyopathy, heart failure with preserved ejection fraction, as well as the prognostic value of MRE in patients with cardiac amyloidosis. In addition, this study motivates future investigation of 3D high‐frequency cardiac MRE in different patient cohorts, in therapy monitoring studies, and future prognostic evaluation studies where myocardial stiffness measurements could play a potential role in disease progression.
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